This article is more than 5 years old. Information may no longer be current.
ThyPRO showed favorable responsiveness for QoL, treatment detection
The ThyPRO quality of life measure had favorable responsiveness and was able to detect treatment for benign thyroid diseases, according to recent study findings published in The Journal of Clinical Endocrinology & Metabolism.
Torquil Watt, MD, PhD, of the department of endocrinology at Copenhagen University Hospital Rigshospitalet in Denmark, and colleagues evaluated 435 people undergoing treatment using the ThyPRO, a patient-reported outcomes measure, and SF-36 Health Survey at baseline and 6 months following treatment initiation to determine responsiveness of thyroid-related quality of life (QoL). Three thyroid patient groups were measured for responsiveness including hyperthyroidism (n=66) and hypothyroidism (n=84) rendered euthyroid after medical therapy and patients with detectable non-toxic goiter that was treated with surgery or radioactive iodine as well as remaining euthyroid (n=62).
For both hyper- and hypothyroidism, ThyPRO showed good responsiveness for all QoL aspects. ThyPRO also resulted in good responsiveness for physical, mental symptoms and overall QoL for non-toxic goiter.
ThyPRO also showed better responsiveness for treatment compared with the SF-36 Health Survey for all scales except one.
“In conclusion, we found that ThyPRO has very good responsiveness, and based on the previously conducted validation studies and the present study, we recommend its use in future clinical studies, trials, as well as in daily clinical practice,” the researchers wrote. “Such studies should further evaluate the relationships between clinical variable and QoL, as measured by ThyPRO. We recommend using this instrument if evaluations of changes and comparisons of differences in changes, as eg, in randomized clinical trials, are important. If greater emphasis is placed on comparability of QoL with other patient groups, a generic instrument such as SF-36 can be utilized and supplemented with the most important ThyPRO scales for a particular intervention.”
Disclosure: See the full study for a complete list of the researchers’ relevant financial disclosures.